Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
REPLACE is a phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) for the first-line treatment of hepatocellular carcinoma (HCC or liver cancer). Approximately 496 patients in around 80 clinical sites worldwide will be randomized to receive either:- Investigational arm: Regorafenib in combination with pembrolizumab - Control arm: Transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) In both arms, patients will receive trial treatment until progressive disease, unacceptable toxicity, deterioration of patient's condition that warrants permanent trial treatment discontinuation or other treatment discontinuation criteria is met. After trial treatment discontinuation, subsequent treatment will be administered according to the Investigator's clinical judgment.
- Signed and dated Patient Informed Consent Form (PICF)
- ≥ 18 years-old at the time of PICF signature
- Confirmed diagnosis of HCC
- Intermediate-stage HCC, defined as follows:
- Multinodular HCC localized to the liver
- No evidence of MVI or EHS
- Not amenable to curative treatment
- Child-Pugh Class A
- ECOG PS 0 or 1
- ALBI grade 1 or 2
- Beyond up-to-seven criteria
- Disease amenable to TACE or TARE and no contradiction to intra-arterial treatment
- Measurable disease by CT or MRI as per RECIST 1.1
- No prior systemic therapy or loco-regional therapy for HCC
- Adequate hematologic and organ function
- Willing and able to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures
- Women of childbearing potential (CBP) must have confirmed negative serum pregnancy test
- Use of highly-effective contraceptive methods in women of CBP and men
- Patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection are eligible if they meet criteria as defined within the protocol
- No measurable tumor of a diffuse infiltrative HCC type.
- Fibrolamellar HCC, sarcomatoid HCC or mixed hepatocellular/ cholangiocarcinoma subtypes.
- Clinically meaningful ascites.
- Prior treatment with regorafenib, a PD-1, PD-L1/PD-L2, or cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior to randomization.
- Active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids.
- Requirement of systemic treatment with either corticosteroids or other immunosuppressive medications ≤ 14 days prior to randomization.
- Interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, or clinically significant acute lung diseases.
- Cardiovascular conditions as defined within the protocol.
- Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed ≤ 2 years before randomization.
- Persistent proteinuria of NCI-CTCAE v5.0 Grade 3.
- Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.
Join this Trial
- UCLA Alhambra
- UCLA Santa Monica